

## Press Release

# ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd's ACCELERATOR program

Lund, Sweden, May 4, 2016

ImmuneBiotech AB, a gut microbiota therapy company, is pleased to announce that it has been awarded a grant by Innovationskontor Syd to support the development of a probiotic based therapy for one of the most prevalent, wide spread diseases, Irritable Bowel Syndrome (IBS).

The ACCELERATOR program's decision to support ImmuneBiotech is based on the company's potential to successfully develop a product capable of providing an effective therapy for IBS.

“I'm extremely pleased with the positive evaluation from Innovationskontor Syd. For me, it is another confirmation that our work to design a new product for the treatment of IBS using our platform expertise and our own probiotic strains is acknowledged by external experts” said ImmuneBiotech's CEO Shahram Lavasani.

### **About ImmuneBiotech AB**

ImmuneBiotech AB discovers and develops novel therapeutics based on probiotic lactic acid bacteria and synbiotic formulations targeting the gut microbiota and the immune system. There is growing evidence verifying the importance of the gut microbiota in several challenging diseases, now translating to a new class of microbiome targeting therapeutics. ImmuneBiotech is one of the forerunners in this field.

ImmuneBiotech has a platform consisting of a proprietary library of unique strains of probiotic lactobacilli, the technologies to select for strains with optimal immune modulatory functions and the know-how to design novel therapeutic bacterial combinations for use in specific diseases. The company has a pre-clinical stage pipeline of therapeutic lactobacilli combinations for the treatments of chronic inflammatory and infectious diseases.

### **About Innovationskontor Syd's ACCELERATOR program**

The accelerator program aims to support start-up innovation companies. For more information please refer to the following link: [www.iks Syd.se/finansiering/accelerator](http://www.iks Syd.se/finansiering/accelerator).

Shahram Lavasani, CEO  
s.lavasani@immunebiotech.com  
+46 707 40 86 61  
ImmuneBiotech AB

ImmuneBiotech AB  
Lund Life Science Incubator  
Medicon Village  
SE-223 81 Lund, Sweden  
Visitor address: Scheelevägen 2  
[www.immunebiotech.com](http://www.immunebiotech.com)